Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs

eLife

Volumn 4, Issue OCTOBER2015, 2015, Pages

  Malatinkova, Eva ^a   De Spiegelaere, Ward ^a   Bonczkowski, Pawel ^a   Kiselinova, Maja ^a   Vervisch, Karen ^a   Trypsteen, Wim ^a   Johnson, Margaret ^b   Verhofstede, Chris ^c   De Looze, Danny ^a   Murray, Charles ^b   Kinloch de Loes, Sabine ^b   Vandekerckhove, Linos ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS DNA;

ADULT; ARTICLE; CD4 CD8 RATIO; CROSS-SECTIONAL STUDY; FEMALE; GENE AMPLIFICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; IMMUNOLOGICAL PARAMETERS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RECTUM; RECTUM BIOPSY; SEROCONVERSION; TREATMENT DURATION; VIREMIA; VIRUS CELL INTERACTION; VIRUS DNA CELL DNA INTERACTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSCRIPTION; ZOONOSIS; BLOOD; COMPARATIVE STUDY; HIV INFECTIONS; ISOLATION AND PURIFICATION; MIDDLE AGED; PROCEDURES; PROVIRUS; SECONDARY PREVENTION; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROVIRUSES; RECTUM; SECONDARY PREVENTION; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84949818984     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.09115     Document Type: Article

References (70)

1. Alexaki A, Liu Y, Wigdahl B. 2008. Cellular reservoirs of HIV-1 and their role in viral persistence. Current HIV Research 6:388-400. doi: 10.2174/157016208785861195
2. Ananworanich J, DubéK, Chomont N. 2015. How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs? Current Opinion in HIV and AIDS 10:18-28. doi: 10.1097/COH.0000000000000122
3. Ananworanich J, Schuetz A, Vandergeeten C, Sereti I, de Souza M, Rerknimitr R, Dewar R, Marovich M, van Griensven F, Sekaly R, Pinyakorn S, Phanuphak N, Trichavaroj R, Rutvisuttinunt W, Chomchey N, Paris R, Peel S, Valcour V, Maldarelli F, Chomont N, Michael N, Phanuphak P, Kim JH. RV254/SEARCH 010 Study Group. 2012. Impact of multi-targeted antiretroviral treatment on gut t cell depletion and HIV reservoir seeding during acute HIV infection. PloS One 7:e33948 doi: 10.1371/journal.pone.0033948.t002
4. Anton PA, Mitsuyasu RT, Deeks SG, Scadden DT, Wagner B, Huang C, Macken C, Richman DD, Christopherson C, Borellini F, Lazar R, Hege KM. 2003. Multiple measures of HIV burden in blood and tissue are correlated wiTheach other but not with clinical parameters in aviremic subjects. AIDS (London, England) 17:53-63. doi: 10.1097/00002030-200301030-00008
5. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482-485. doi: 10.1038/nature11286
6. Autran B, Descours B, Avettand-Fenoel V, Rouzioux C. 2011. Elite controllers as a model of functional cure. Current Opinion in HIV and AIDS 6:181-187. doi: 10.1097/COH.0b013e328345a328
7. Avettand-Fenoel V, Prazuck T, Hocqueloux L, Melard A, Michau C, Kerdraon R, Agoute E, Rouzioux C. 2008. HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors. AIDS (London, England) 22:1880-1882. doi: 10.1097/QAD.0b013e32830fbdbc
8. Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, Busch MP, Deeks SG, Carrington M, O’Doherty U, Kostman J, Montaner LJ. 2013. Pegylated interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. The Journal of Infectious Diseases 207:213-222. doi: 10.1093/infdis/jis663
9. Bednar MM, Sturdevant CB, Tompkins LA, Arrildt KT, Dukhovlinova E, Kincer LP, Swanstrom R. 2015. Compartmentalization, viral evolution, and viral latency of HIV in the CNS. Current HIV/AIDS Reports 12:262-271. doi: 10.1007/s11904-015-0265-9
10. Blankson JN, Bailey JR, Thayil S, Yang H-C, Lassen K, Lai J, Gandhi SK, Siliciano JD, Williams TM, Siliciano RF. 2007. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. Journal of Virology 81:2508-2518. doi: 10.1128/JVI.02165-06
11. Bruner KM, Hosmane NN, Siliciano RF. 2015. Towards an HIV-1 cure: measuring the latent reservoir. Trends in Microbiology 23:192-203. doi: 10.1016/j.tim.2015.01.013
12. Brussel A, Mathez D, Broche-Pierre S, Lancar Rémi, Calvez T, Sonigo P, Leibowitch J. 2003. Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection. AIDS (London, England) 17:645-652. doi: 10.1097/00002030-200303280-00001
13. Buzon MJ, Martin-Gayo E, Pereyra F, Ouyang Z, Sun H, Li JZ, Piovoso M, Shaw A, Dalmau J, Zangger N, Martinez-Picado J, Zurakowski R, Yu XG, Telenti A, Walker BD, Rosenberg ES, Lichterfeld M. 2014. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 t cells. Journal of Virology 88:10056-10065. doi: 10.1128/JVI.01046-14
14. Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M, Palmer S, Stevenson M, Clotet B, Blanco Julià, Martinez-Picado J. 2010. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nature Medicine 16:460-465. doi: 10.1038/nm.2111
15. Ceelen L, de Craene J, de Spiegelaere W. 2014. Evaluation of normalization strategies used in real-time quantitative PCR experiments in HepaRG cell line studies. Clinical Chemistry 60:451-454. doi: 10.1373/clinchem.2013.209478
16. Cellerai C, Harari A, Stauss H, Yerly S, Geretti A-M, Carroll A, Yee T, Ainsworth J, Williams I, Sweeney J, Freedman A, Johnson M, Pantaleo G, Kinloch-de Loes S. 2011. Early and prolonged antiretroviral therapy is associated with an HIV-1-specific t-cell profile comparable to that of long-term non-progressors. PloS One 6: e18164 doi: 10.1371/journal.pone.0018164.s002
17. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel M-R, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy J-P, Haddad EK, Sékaly R-P. 2009. HIV reservoir size and persistence are driven by t cell survival and homeostatic proliferation. Nature Medicine 15:893-900. doi: 10.1038/nm.1972
18. Chun T-W, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, Kottilil S, Moir S, Mican JM, Mullins JI, Ward DJ, Kovacs JA, Mannon PJ, Fauci AS. 2008. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. The Journal of Infectious Diseases 197:714-720. doi: 10.1086/527324
19. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America 94:13193-13197. doi: 10.1073/pnas.94.24.13193
20. Cohn LB, Silva IT, Oliveira TY, Rosales RA, Parrish EH, Learn GH, Hahn BH, Czartoski JL, Mcelrath MJ, Lehmann C, Klein F, Caskey M, Walker BD, Siliciano JD, Siliciano RF, Jankovic M, Nussenzweig MC. 2015. HIV-1 integration landscape during latent and active infection. Cell 160:420-432. doi: 10.1016/j.cell.2015.01.020
21. de Spiegelaere W, Malatinkova E, Lynch L, van Nieuwerburgh F, Messiaen P, O’Doherty U, Vandekerckhove L. 2014. Quantification of integrated HIV DNA by repetitive-sampling alu-HIV PCR on the basis of poisson statistics. Clinical Chemistry 60:886-895. doi: 10.1373/clinchem.2013.219378
22. Deeks SG, Walker BD. 2007. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27:406-416. doi: 10.1016/j.immuni.2007.08.010
23. di Stefano M, Favia A, Monno L, Lopalco P, Caputi O, Scardigno AC, Pastore G, Fiore JR, Angarano G. 2001. Intracellular and cell-free (infectious) HIV-1 in rectal mucosa. Journal of Medical Virology 65:637-643. doi: 10.1002/jmv.2084
24. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, Mcmahon J, Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin Rémi, Procopio FA, Zeidan J, Palmer S, Odevall L, Johnstone RW, Martin BP, Sinclair E, Deeks SG, Hazuda DJ, Cameron PU, Sékaly R-P, Lewin SR. 2014. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathogens 10:e1004473 doi: 10.1371/journal.ppat.1004473.s010
25. Fauci AS, Folkers GK. 2009. Investing to meet the scientific challenges of HIV/AIDS. Health Affairs (Project Hope) 28:1629-1641. doi: 10.1377/hlthaff.28.6.1629
26. Fernández Guerrero ML, Rivas P, Molina M, Garcia R, de Górgolas M. 2005. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 41:390-394. doi: 10.1086/431487
27. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, et al. 1999. Latent infection of CD4+ t cells provides a mechanism for lifelong persistence of HIV-1, even in patietns on effective combination therapy. Nat Med 3:512-517.
28. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (New York, N.Y.) 278:1295-1300. doi: 10.1126/science.278.5341.1295
29. Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, Beilman GJ, Khoruts A, Thorkelson A, Schmidt TE, Anderson J, Perkey K, Stevenson M, Perelson AS, Douek DC, Haase AT, Schacker TW. 2014. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proceedings of the National Academy of Sciences of the United States of America 111:2307-2312. doi: 10.1073/pnas.1318249111
30. Goicoechea M, Smith DM, Liu L, May S, Tenorio AR, Ignacio CC, Landay A, Haubrich R. 2006. Determinants of CD4+ t cell recovery during suppressive antiretroviral therapy: association of immune activation, t cell maturation markers, and cellular HIV-1 DNA. The Journal of Infectious Diseases 194:29-37. doi: 10.1086/504718
31. Graf EH, Mexas AM, Yu JJ, Shaheen F, Liszewski MK, di Mascio M, Migueles SA, Connors M, O’Doherty U. 2011. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and offHAART. PLoS Pathogens 7 doi: 10.1371/journal.ppat.1001300
32. Hatano H, Jain V, Hunt PW, Lee T-H, Sinclair E, do TD, Hoh R, Martin JN, Mccune JM, Hecht F, Busch MP, Deeks SG. 2013a. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (pD-1)-expressing CD4+ t cells. The Journal of Infectious Diseases 208:50-56. doi: 10.1093/infdis/jis630
33. Hatano H, Somsouk M, Sinclair E, Harvill K, Gilman L, Cohen M, Hoh R, Hunt PW, Martin JN, Wong JK, Deeks SG, Yukl SA. 2013b. Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers. AIDS (London, England) 27:2255-2260. doi: 10.1097/QAD.0b013e328362692f
34. Hocqueloux L, Avettand-Fènoël V, Jacquot S, Prazuck T, Legac E, Mélard A, Niang M, Mille C, LeMoal Gwenaël, Viard J-P, Rouzioux C, AC32 (Coordinated Action on HIV Reservoirs) of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS). 2013. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal t cell counts. The Journal of Antimicrobial Chemotherapy 68:1169-1178. doi: 10.1093/jac/dks533
35. Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh L-E, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink H-J, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S, QUEST Study Group. 2007. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 45:381-390. doi: 10.1086/519428
36. Hong FF, Mellors JW. 2015. Changes in HIV reservoirs during long-term antiretroviral therapy. Current Opinion in HIV and AIDS 10:43-48. doi: 10.1097/COH.0000000000000119
37. Hunt PW, Hatano H, Sinclair E, Lee T-H, Busch MP, Martin JN, Mccune JM, Deeks SG. 2011. HIV-specific CD4+ t cells may contribute to viral persistence in HIV controllers. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 52:681-687. doi: 10.1093/cid/ciq202
38. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina J-M, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. 2015. Initiation of antiretroviral therapy in early asymptomatic HIV infection. The New England Journal of Medicine 373:795-807. doi: 10.1056/NEJMoa1506816
39. Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, Sinclair E, Epling L, Lee T-H, Busch MP, Mccune JM, Pilcher CD, Hecht FM, Deeks SG. 2013. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower t-cell activation and smaller HIV reservoir size. The Journal of Infectious Diseases 208: 1202-1211. doi: 10.1093/infdis/jit311
40. Josefsson L, von Stockenstrom S, Faria NR, Sinclair E, Bacchetti P, Killian M, Epling L, Tan A, Ho T, Lemey P, Shao W, Hunt PW, Somsouk M, Wylie W, Douek DC, Loeb L, Custer J, Hoh R, Poole L, Deeks SG, Hecht F, Palme S. 2013. The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proceedings of the National Academy of Sciences of the United States of America 110:E4987-E4996. doi: 10.1073/pnas.1308313110
41. Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C, Miller M, Vella S, Schmitz JE, Ahlers J, Richman DD, Sekaly RP. 2013. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (London, England) 381:2109-2117. doi: 10.1016/S0140-6736(13)60104-X
42. Kiselinova M, Pasternak AO, de Spiegelaere W, Vogelaers D, Berkhout B, Vandekerckhove L. 2014. Comparison of droplet digital PCR and seminested real-time PCR for quantification of cell-associated HIV-1 RNA. PloS One 9:e85999 doi: 10.1371/journal.pone.0085999.s006
43. Laanani M, Ghosn J, Essat A, Melard A, Seng R, Gousset M, Panjo H, Mortier E, Girard P-M, Goujard C, Meyer L, Rouzioux C, Agence Nationale de Recherche sur le Sida PRIMO Cohort Study Group. 2015. Impact of the timing of initiation of antiretroviral therapy during primary HIV-1 infection on the decay of cell-associated HIV-DNA. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 60: 1715-1721. doi: 10.1093/cid/civ171
44. Liszewski MK, Yu JJ, O’Doherty U. 2009. Detecting HIV-1 integration by repetitive-sampling alu-gag PCR. Methods (San Diego, Calif.) 47:254-260. doi: 10.1016/j.ymeth.2009.01.002
45. Lizée G, Aerts JL, Gonzales MI, Chinnasamy N, Morgan RA, Topalian SL. 2003. Real-time quantitative reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression. Human Gene Therapy 14:497-507. doi: 10.1089/104303403764539387
46. Malatinkova E, Kiselinova M, Bonczkowski P, Trypsteen W, Messiaen P, Vermeire J, Verhasselt B, Vervisch K, Vandekerckhove L, de Spiegelaere W. 2015. Accurate quantification of episomal HIV-1 two-long terminal repeat circles by use of optimized DNA isolation and droplet digital PCR. Journal of Clinical Microbiology 53: 699-701. doi: 10.1128/JCM.03087-14
47. Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, Spindler J, Ferris AL, Mellors JW, Kearney MF, Coffin JM, Hughes SH. 2014. HIV latency. specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science (New York, N.Y.) 345:179-183. doi: 10.1126/science.1254194
48. Messiaen P, de Spiegelaere W, Alcami J, Vervisch K, van Acker P, Verhasselt B, Meuwissen P, Calonge E, Gonzalez N, Gutierrez-Rodero F, Rodriguez-Martín C, Sermijn E, Poppe B, Vogelaers D, Verhofstede C, Vandekerckhove L. 2012. Characterization of LEDGF/p75 genetic variants and association with HIV-1 disease progression. PloS One 7:e50204 doi: 10.1371/journal.pone.0050204.s002
49. Murray JM, Zaunders JJ, Mcbride KL, Xu Y, Bailey M, Suzuki K, Cooper DA, Emery S, Kelleher AD, Koelsch KK, PINT Study Team. 2014. HIV DNA subspecies persist in both activated and resting memory CD4+ t cells during antiretroviral therapy. Journal of Virology 88:3516-3526. doi: 10.1128/JVI.03331-13
50. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS. 2008. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America 105:3879-3884. doi: 10.1073/pnas.0800050105
51. Pasternak AO, Lukashov VV, Berkhout B. 2013. Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology 10:41 doi: 10.1038/nature11286
52. Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF. 2002. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. Journal of Virology 76:4138-4144. doi: 10.1128/JVI.76.8.4138-4144.2002
53. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, Winckelmann A, Palmer S, Dinarello C, Buzon M, Lichterfeld M, Lewin SR, Østergaard L, Søgaard OS. 2014. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. The Lancet. HIV 1:e13-e21. doi: 10.1016/S2352-3018(14)70014-1
54. Saag M, Deeks SG. 2010. How do HIV elite controllers do what they do? Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 51:239-241. doi: 10.1086/653678
55. Salgado M, Rabi SA, O’Connell KA, Buckheit RW, Bailey JR, Chaudhry AA, Breaud AR, Marzinke MA, Clarke W, Margolick JB, Siliciano RF, Blankson JN. 2011. Prolonged control of replication-competent dual-tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy. Retrovirology 8:97 doi: 10.1186/1742-4690-8-97
56. Schmid A, Gianella S, von Wyl V, Metzner KJ, Scherrer AU, Niederöst B, Althaus CF, Rieder P, Grube C, Joos B, Weber R, Fischer M, Günthard HF. 2010. Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. PloS One 5:e13310 doi: 10.1371/journal.pone.0013310.s003
57. Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, Ferre AL, Hayes TL, Somsouk M, Hsue PY, van Natta ML, Meinert CL, Lederman MM, Hatano H, Jain V, Huang Y, Hecht FM, Martin JN, Mccune JM, Moreno S, Deeks SG. 2014. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered t cell subsets, heightened CD8+ t cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathogens 10:e1004078 doi: 10.1371/journal.ppat.1004078.s011
58. Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M. 2011. Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathogens 7:e1001303 doi: 10.1371/journal.ppat.1001303.s009
59. Sharkey M, Triques K, Kuritzkes DR, Stevenson M. 2005. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. Journal of Virology 79:5203-5210. doi: 10.1128/JVI.79.8.5203-5210.2005
60. Sharkey M. 2013. Tracking episomal HIV DNA: implications for viral persistence and eradication of HIV. Current Opinion in HIV and AIDS 8:93-99. doi: 10.1097/COH.0b013e32835d08c2
61. Sturdevant CB, Joseph SB, Schnell G, Price RW, Swanstrom R, Spudich S, Lifson J. 2015. Compartmentalized replication of R5 t cell-tropic HIV-1 in the central nervous system early in the course of infection. PLOS Pathogens 11:e1004720 doi: 10.1371/journal.ppat.1004720.s006
62. Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel Véronique, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard J-P, Boufassa F, Lambotte O, Goujard Cécile, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C, ANRS VISCONTI Study Group. 2013. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathogens 9:e1003211 doi: 10.1371/journal.ppat.1003211.s007
63. van Gulck E, Bracke L, Heyndrickx L, Coppens S, Atkinson D, Merlin Céline, Pasternak A, Florence E, Vanham G. 2012. Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients. PloS One 7:e37792 doi: 10.1371/journal.pone.0037792.s001
64. Vandesompele J, de Preter K, Pattyn F, Poppe B, van Roy N, de Paepe A, Speleman F. 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 18:7
65. Wagner TA, Mclaughlin S, Garg K, Cheung CYK, Larsen BB, Styrchak S, Huang HC, Edlefsen PT, Mullins JI, Frenkel LM. 2014. HIV latency. proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science (New York, N.Y.) 345:570-573. doi: 10.1126/science.1256304
66. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, Hesselgesser J, Irrinki A, Murry JP, Stepan G, Stray KM, Tsai A, Yu H, Spindler J, Kearney M, Spina CA, Mcmahon D, Lalezari J, Sloan D, Mellors J, Geleziunas R, Cihlar T. 2014. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 t cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathogens 10:e1004071 doi: 10.1371/journal.ppat.1004071.s008
67. Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, Kinloch S, Cooper D, Schechter M, Tambussi G, Fidler S, Carrington M, Babiker A, Weber J, Koelsch KK, Kelleher AD, Phillips RE, Frater J, SPARTACTrial Investigators. 2014. HIV-1 DNA predicts disease progression and post-treatment virological control. eLife 3: e03821 doi: 10.7554/eLife.03821.019
68. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (New York, N.Y.) 278: 1291-1295. doi: 10.1126/science.278.5341.1291
69. Yu JJ, Wu TL, Liszewski MK, Dai J, Swiggard WJ, Baytop C, Frank I, Levine BL, Yang W, Theodosopoulos T, O’Doherty U. 2008. A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients. Virology 379:78-86. doi: 10.1016/j.virol.2008.05.030
70. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, Choi ALM, Girling V, Ho T, Li P, Fujimoto K, Lampiris H, Hare CB, Pandori M, Haase AT, Günthard HF, Fischer M, Shergill AK, Mcquaid K, Havlir DV, Wong JK. 2010. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. The Journal of Infectious Diseases 202:1553-1561. doi: 10.1086/656722